Status:
RECRUITING
The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin
Lead Sponsor:
Shanghai Dermatology Hospital
Conditions:
Sensitive Skin
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin
Eligibility Criteria
Inclusion
- Sensitive skin with a diagnosis of persistent erythema and a lactate irritation test score of 2-3
- No related skin care products including bovine alkaline fibroblast growth factor were used within 1 month before participating in the experiment, and photoelectric treatment measures were not carried out
- Physical sunscreen should be strict during enrollment
Exclusion
- Children
- Have serious heart, liver, kidney, and blood system diseases, and severe immunocompromise
- Patients with mental illness or cancer
- Those who have received glucocorticoids, calcineurin inhibitors, topical small molecule drugs, antibiotics or tretinoin within 3 months
- Those who are allergic to basic fibroblast growth factor gel and its components
- Acute dermatitis of the face and perifolliculitis
Key Trial Info
Start Date :
June 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 18 2024
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT06516939
Start Date
June 10 2024
End Date
July 18 2024
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Skin Disease Hospital
Shanghai, China